vs
Journey Medical Corp（DERM）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
Rumble Inc.的季度营收约是Journey Medical Corp的1.7倍（$27.1M vs $16.1M），Journey Medical Corp净利率更高（-7.8% vs -120.8%，领先113.0%），Journey Medical Corp同比增速更快（27.3% vs -10.5%），过去两年Rumble Inc.的营收复合增速更高（15.2% vs 11.0%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
DERM vs RUM — 直观对比
营收规模更大
RUM
是对方的1.7倍
$16.1M
营收增速更快
DERM
高出37.8%
-10.5%
净利率更高
DERM
高出113.0%
-120.8%
两年增速更快
RUM
近两年复合增速
11.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $27.1M |
| 净利润 | $-1.2M | $-32.7M |
| 毛利率 | — | 5.5% |
| 营业利润率 | -2.8% | -131.1% |
| 净利率 | -7.8% | -120.8% |
| 营收同比 | 27.3% | -10.5% |
| 净利润同比 | -182.0% | 86.2% |
| 每股收益（稀释后） | $-0.04 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMRUM
| Q4 25 | $16.1M | $27.1M | ||
| Q3 25 | $17.0M | $24.8M | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $13.1M | $23.7M | ||
| Q4 24 | $12.6M | $30.2M | ||
| Q3 24 | $14.6M | $25.1M | ||
| Q2 24 | $14.9M | $22.5M | ||
| Q1 24 | $13.0M | $17.7M |
净利润DERMRUM
| Q4 25 | $-1.2M | $-32.7M | ||
| Q3 25 | $-2.3M | $-16.3M | ||
| Q2 25 | $-3.8M | — | ||
| Q1 25 | $-4.1M | $-2.7M | ||
| Q4 24 | $1.5M | $-236.8M | ||
| Q3 24 | $-2.4M | $-31.5M | ||
| Q2 24 | $-3.4M | $-26.8M | ||
| Q1 24 | $-10.4M | $-43.3M |
毛利率DERMRUM
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | 82.3% | -14.2% | ||
| Q3 24 | 63.9% | -45.4% | ||
| Q2 24 | 56.0% | -58.8% | ||
| Q1 24 | 47.7% | -79.5% |
营业利润率DERMRUM
| Q4 25 | -2.8% | -131.1% | ||
| Q3 25 | -9.0% | -113.6% | ||
| Q2 25 | -19.2% | — | ||
| Q1 25 | -25.3% | -153.5% | ||
| Q4 24 | 17.7% | -80.1% | ||
| Q3 24 | -19.8% | -131.0% | ||
| Q2 24 | -19.7% | -172.7% | ||
| Q1 24 | -77.4% | -197.4% |
净利率DERMRUM
| Q4 25 | -7.8% | -120.8% | ||
| Q3 25 | -13.6% | -65.7% | ||
| Q2 25 | -25.3% | — | ||
| Q1 25 | -31.0% | -11.2% | ||
| Q4 24 | 12.1% | -783.2% | ||
| Q3 24 | -16.3% | -125.9% | ||
| Q2 24 | -22.6% | -119.2% | ||
| Q1 24 | -80.1% | -244.1% |
每股收益（稀释后）DERMRUM
| Q4 25 | $-0.04 | $-0.13 | ||
| Q3 25 | $-0.09 | $-0.06 | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.18 | $-0.01 | ||
| Q4 24 | $0.10 | $-1.17 | ||
| Q3 24 | $-0.12 | $-0.15 | ||
| Q2 24 | $-0.17 | $-0.13 | ||
| Q1 24 | $-0.53 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $237.9M |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $274.8M |
| 总资产 | $94.6M | $336.8M |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMRUM
| Q4 25 | $24.1M | $237.9M | ||
| Q3 25 | $24.9M | $269.8M | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | $301.3M | ||
| Q4 24 | $20.3M | $114.0M | ||
| Q3 24 | $22.5M | $132.0M | ||
| Q2 24 | $23.9M | $154.2M | ||
| Q1 24 | $24.1M | $183.8M |
总债务DERMRUM
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
股东权益DERMRUM
| Q4 25 | $31.9M | $274.8M | ||
| Q3 25 | $25.9M | $302.2M | ||
| Q2 25 | $19.2M | — | ||
| Q1 25 | $21.5M | $339.6M | ||
| Q4 24 | $20.1M | $-63.1M | ||
| Q3 24 | $10.9M | $166.1M | ||
| Q2 24 | $11.3M | $192.7M | ||
| Q1 24 | $13.0M | $210.7M |
总资产DERMRUM
| Q4 25 | $94.6M | $336.8M | ||
| Q3 25 | $85.2M | $367.2M | ||
| Q2 25 | $81.2M | — | ||
| Q1 25 | $85.0M | $391.1M | ||
| Q4 24 | $80.2M | $195.3M | ||
| Q3 24 | $64.0M | $217.2M | ||
| Q2 24 | $65.2M | $243.2M | ||
| Q1 24 | $66.6M | $263.0M |
负债/权益比DERMRUM
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-31.7M |
| 自由现金流率自由现金流/营收 | — | -117.2% |
| 资本支出强度资本支出/营收 | — | 8.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-70.8M |
8季度趋势，按日历期对齐
经营现金流DERMRUM
| Q4 25 | $-6.3M | $-29.4M | ||
| Q3 25 | $-2.4M | $-10.6M | ||
| Q2 25 | $-942.0K | — | ||
| Q1 25 | $-2.8M | $-14.5M | ||
| Q4 24 | $2.2M | $-12.4M | ||
| Q3 24 | $-1.2M | $-19.1M | ||
| Q2 24 | $-5.2M | $-21.7M | ||
| Q1 24 | $-5.0M | $-33.9M |
自由现金流DERMRUM
| Q4 25 | — | $-31.7M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-14.6M | ||
| Q4 24 | — | $-12.4M | ||
| Q3 24 | — | $-19.9M | ||
| Q2 24 | — | $-23.1M | ||
| Q1 24 | — | $-34.3M |
自由现金流率DERMRUM
| Q4 25 | — | -117.2% | ||
| Q3 25 | — | -48.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -61.7% | ||
| Q4 24 | — | -40.9% | ||
| Q3 24 | — | -79.5% | ||
| Q2 24 | — | -102.8% | ||
| Q1 24 | — | -193.3% |
资本支出强度DERMRUM
| Q4 25 | — | 8.5% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 6.1% | ||
| Q1 24 | — | 2.4% |
现金转化率DERMRUM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
